050 Eotaxin-1 and Matrix Metalloproteinase-9 Are Critical in Anti-Bp180 IgE-induced Experimental Bullous Pemphigoid

T. Jordan,J. Chen,N. Li,S. Burette,D. A. Culton,S. Geng,P. Googe,N. Thomas,L. Diaz,Z. Liu
DOI: https://doi.org/10.1016/j.jid.2022.05.104
IF: 7.59
2022-01-01
Journal of Investigative Dermatology
Abstract:Bullous pemphigoid (BP) is the most common autoimmune blistering disease characterized by chronic subepidermal blistering, autoantibodies directed against hemidesmosomal components, and a predominant eosinophil infiltrate. BP autoantibodies recognize two hemidesmosomal proteins of basal keratinocytes: BP230 (also termed BPAG1) and BP180 (also termed BPAG2 or collagen XVII) with the NC16A domain of the human BP180 antigen containing the major autoantibody-reactive epitopes. Anti-BP180 autoantibodies belong to IgG and IgE isotypes. We have previously demonstrated the pathogenicity of anti-NC16A IgG and IgE autoantibodies from BP patients using antibody passive transfer animal models. We have shown that anti-NC16A IgE autoantibodies from BP patients recruit eosinophils and induce eosinophil-dependent BP in double humanized NC16A and human IgE receptor (termed NC16A/hFcεRI) mice. In this study, we find that pathogenic anti-NC16A IgE significantly increases levels of key eosinophil chemoattractants, eotaxin 1 and eotaxin 2, and matrix metalloproteinase 9 (MMP-9) in the lesional skin of diseased mice. Treatment with neutralizing antibody against murine eotaxin 1, but not murine eotaxin 2, significantly reduces the pathogenic activity of anti-NC16A IgE. Blockade of the main eotaxin receptor, CCR3, using a small molecule inhibitor also drastically reduces anti-NC16A IgE-induced BP disease severity. Furthermore, NC16A/hFcεRI mice lacking MMP-9 are resistant to anti-NC16A IgE-induced BP. Finally, we find significantly higher levels of eotaxins in blister fluid and sera of BP patients compared to normal controls. These findings identify eotaxin 1 and MMP-9 as key players in experimental BP and potential new therapeutic targets for this disease.
What problem does this paper attempt to address?